Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA panel narrowly backs new use of UCB's arthritis drug
FDA panel narrowly backs new use of UCB's arthritis drug
FDA panel narrowly backs new use of UCB's arthritis drug
Submitted by
admin
on July 24, 2013 - 9:49am
Source:
Reuters
News Tags:
FDA
UCB Pharmaceuticals
rheumatoid arthritis
certolizumab
Headline:
FDA panel narrowly backs new use of UCB's arthritis drug
Do Not Allow Advertisers to Use My Personal information
